ethyl 2-azabicyclo[2.2.2]octane-3-carboxylate | 385808-61-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-azabicyclo[2.2.2]octane-3-carboxylate
• 英文别名: ethyl 2-azadicyclo[2.2.2]octane-3-carboxylate；3-(S)-carbethoxy-2-azabicyclo[2.2.2]octane；2-azabicyclo[2.2.2.]octane-3-carboxylic acid, ethyl ester
• CAS: 385808-61-7
• 化学式: C₁₀H₁₇NO₂
• mdl: MFCD20542627
• 分子量: 183.25
• InChiKey: WWRUCFABCHBARW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-azabicyclo[2.2.2]octane-3-carboxylate 在 lithium aluminium tetrahydride 、 铁粉 、 氯化铵 、 溶剂黄146 、 三乙胺 、 锌 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 (4-amino-2-chlorophenyl)(6,6a,7,8,9,10-hexahydro-7,10-ethanobenzo[e]pyrido[1,2-a][1,4]diazepin-5(12H)-yl)methanone
  参考文献：
  名称：

  Bridged bicyclic vasopressin receptor antagonists with V2-Selective or dual V1a/V2 activity

  摘要：

  The synthesis and biological testing of a novel series of nonpeptide vasopressin receptor antagonists, containing a bridged bicyclic nucleus, are reported. Variation of substituents (R-1-R-3) in general formula 3, and the configuration of the stereo-center, resulted in potent V-2-selective (e.g., 4) and balanced dual V-1a/V-2 (e.g., 10) compounds. Data from receptor binding, cell-based functional, and in vivo assays are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00649-2
• 作为产物：
  描述：

  2-aza-2-(1-phenylethyl)-3-ethoxycarbonyl-<2,2,2>-bicyclooct-5-ene 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 ethyl 2-azabicyclo[2.2.2]octane-3-carboxylate
  参考文献：
  名称：

  Bridged bicyclic vasopressin receptor antagonists with V2-Selective or dual V1a/V2 activity

  摘要：

  The synthesis and biological testing of a novel series of nonpeptide vasopressin receptor antagonists, containing a bridged bicyclic nucleus, are reported. Variation of substituents (R-1-R-3) in general formula 3, and the configuration of the stereo-center, resulted in potent V-2-selective (e.g., 4) and balanced dual V-1a/V-2 (e.g., 10) compounds. Data from receptor binding, cell-based functional, and in vivo assays are presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00649-2

文献信息

• Fused cyclic modulators of nuclear hormone receptor function
  申请人：——

  公开号：US20030114420A1

  公开（公告）日：2003-06-19

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合环化合物，使用这种化合物治疗与核激素受体相关疾病（如癌症和免疫紊乱）的方法，以及含有这种化合物的药物组合物。
• CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
  申请人：Borriello Manuela

  公开号：US20150087626A1

  公开（公告）日：2015-03-26

  There is described a novel group of cyclic amine derivative compounds, having an EP 4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP 4 subtype of PGE 2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

  本发明描述了一组新型的环胺衍生物化合物，具有EP4受体拮抗活性，特别是用于治疗或缓解前列腺素E介导的疾病的药物化合物。因此，本发明涉及的是新型化合物，它们是PGE2受体的EP4亚型的选择性拮抗剂，具有镇痛和抗炎活性，其制备过程，包含它们的药物组合物以及它们作为药物的使用，例如用于治疗或缓解急性疼痛、慢性疼痛、骨关节炎、与炎症相关的疾病如关节炎、类风湿性关节炎、癌症、偏头痛和子宫内膜异位症的前列腺素E介导的疾病。
• [EN] CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS AMINÉS CYCLIQUES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR EP4
  申请人：ROTTAPHARM SPA

  公开号：WO2013004290A1

  公开（公告）日：2013-01-10

  There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP4 subtype of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.

  本发明描述了一组新型的环状胺衍生物化合物，具有EP4受体拮抗活性，特别是用于治疗或减轻前列腺素E介导的疾病的药物化合物。因此，本发明涉及的是新型化合物，它们是PGE2受体的EP4亚型的选择性拮抗剂，具有镇痛和抗炎活性，其制备过程，包含它们的药物组合物以及它们作为药物的使用，包括用于治疗或减轻前列腺素E介导的疾病，如急性疼痛、慢性疼痛、骨关节炎、与炎症相关的疾病如关节炎、类风湿性关节炎、癌症、偏头痛和子宫内膜异位症。
• [EN] IMPROVED AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS A4 INTEGRIN ANTAGONISTS<br/>[FR] DERIVES D'ACIDES AMINES AZA-BICYCLIQUES A PONTAGE AMELIORES TENANT LIEU D'ANTAGONISTES DE L'INTEGRINE DOLLAR G(A)4
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005042529A1

  公开（公告）日：2005-05-12

  The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful α4 integrin receptor antagonists and, in particular, α4β1 and α4β7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

  本发明涉及具有化学式（I）的氮杂桥环双环化合物及其药学上可接受的盐。这些化合物是有用的α4整合素受体拮抗剂，特别是α4β1和α4β7整合素受体拮抗剂。本发明进一步涉及使用本发明化合物治疗整合素介导的疾病的方法，包括但不限于炎症性疾病、自身免疫性疾病和细胞增殖性疾病的方法，制备这些化合物的方法以及制备其中间体、衍生物和药物组合物的方法。
• Azabicyclo compound matrix metalloprotease inibitor and skin preparation
  申请人：Hiruma Takuya

  公开号：US20050009808A1

  公开（公告）日：2005-01-13

  An azabicyclo compound (I) or a salt thereof in accordance with the present invention has an excellent inhibiting action on matrix metalloproteases (MMPs) activity, and is useful for pharmaceutical, cosmetic and skin external compositions. wherein R is H, alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, acyl, COOR 1 , carbamoyl or SO 2 R 2 (wherein R 1 and R 2 each are alkyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl); X is methylene, ethylene or propylene; and is a single bond or a double bond.

  本发明提供的一种氮杂双环化合物(I)或其盐在抑制基质金属蛋白酶(MMPs)活性方面具有优异的作用，并可用于制药、化妆品和皮肤外用组合物中。其中R为H、烷基、杂基烷基、芳基、杂芳基、芳基烷基、杂芳基烷基、酰基、COOR1、氨基甲酰或SO2R2（其中R1和R2各自为烷基、杂基烷基、芳基、杂芳基、芳基烷基或杂芳基烷基）；X为亚甲基、乙烯基或丙烯基；而表示单键或双键。